Match!
Sanjay Merchant
Janssen Pharmaceutica
5Publications
4H-index
36Citations
Publications 5
Newest
#1Maneesha Mehra (Janssen Pharmaceutica)H-Index: 9
#2Sanjay Merchant (Janssen Pharmaceutica)H-Index: 4
Last.Ravi PotluriH-Index: 6
view all 4 authors...
AbstractIntroduction:Diabetic peripheral neuropathy (DPN) is a debilitating complication of diabetes and accounts for significant morbidity by pre-disposing the foot to ulceration and lower extremity amputation. Using a large US commercial claims database, this study analyzes the drug class usage and co-morbidities associated with DPN as well as estimates the associated economic burden.Methods:Patients older than 18 and diagnosed with DPN were followed longitudinally for 2 years pre- and post-di...
11 CitationsSource
#1Sanjay Merchant (Janssen Pharmaceutica)H-Index: 4
#2L NoeH-Index: 3
Last.Samir H. Mody (Janssen Pharmaceutica)H-Index: 19
view all 7 authors...
Background: Opioids are commonly used to manage chronic pain. Although traditional -opioids are effective in reducing pain, they are often associated with opioid-induced side effects (OISEs) that can limit treatment effectiveness. Studies have shown that tapentadol extended release (ER) has a lower incidence of gastrointestinal adverse events than oxycodone controlled release (CR) at equianalgesic doses. Objective: A model was developed to estimate the budget impact of placing tapentadol ER on a...
11 CitationsSource
#1Nancy Neil (UW: University of Washington)H-Index: 18
#2Sanjay Merchant (Janssen Pharmaceutica)H-Index: 4
Last.Samir H. Mody (Janssen Pharmaceutica)H-Index: 19
view all 5 authors...
AbstractObjective:To evaluate costs and outcomes associated with initial tapentadol ER vs oxycodone CR for the treatment of chronic non-cancer pain (CNCP) in the US.Methods:This study developed a Monte-Carlo simulation based on the scientific foundation established by published models of long-acting opioids (LAO) in patients having moderate-to-severe CNCP. It estimates costs and outcomes associated with the use of tapentadol ER vs oxycodone CR over a 1-year period from the perspective of a US pa...
4 CitationsSource
#1Sanjay Merchant (Janssen Pharmaceutica)H-Index: 4
#2David ProvenzanoH-Index: 2
Last.M. Etropolski (Janssen Pharmaceutica)H-Index: 10
view all 5 authors...
Objective: To evaluate a composite measure for chronic pain that balances pain relief with tolerability. Design: Post hoc meta-analysis of three randomized, multicenter, double-blind studies. Participants: Subjects with moderate-to-severe chronic osteoarthritis knee pain or low back pain who had been randomized to receive active treatment with tapentadol extended release (ER; n = 978) or oxycodone controlled release (CR; n = 999). Twenty-two subjects were excluded, mainly because they did not re...
10 CitationsSource
#1Sanjay Merchant (Janssen Pharmaceutica)H-Index: 4
#2L NoeH-Index: 3
Last.Samir H. Mody (Janssen Pharmaceutica)H-Index: 19
view all 7 authors...
Source
1